USP4 controls neutrophil spreading through stabilising IQGAP1 during lung inflammation.

Summary

Using human ARDS samples and mouse ALI models, the authors show USP4 is upregulated in leukocytes but downregulated in lung parenchyma and controls neutrophil spreading by stabilizing IQGAP1. Pharmacologic targeting of the USP4–IQGAP1 axis (e.g., Vialinin A) emerges as a translational avenue for ARDS secondary to severe pneumonia.

Key Findings

• USP4 expression increases in blood and pulmonary leukocytes from ARDS patients and ALI mice (p=0.049 and p=0.0086) but decreases in mouse lung parenchyma (LPS vs control, p=0.0019).
• USP4 controls neutrophil spreading by stabilizing IQGAP1 during lung inflammation, linking protein homeostasis to leukocyte recruitment.
• Targeting the USP4–IQGAP1 axis with Vialinin A is proposed as a therapeutic strategy for ARDS secondary to severe pneumonia.

Clinical Implications

While preclinical, the USP4–IQGAP1 axis could inform biomarker development and targeted anti-inflammatory therapies for ARDS, warranting testing of USP4 modulators such as Vialinin A in translational models.

Limitations

• Preclinical nature limits direct clinical generalizability
• Abstract does not detail sample sizes or full experimental breadth

Future Directions

Validate USP4–IQGAP1 targeting in additional ARDS models, define pharmacokinetics/safety of Vialinin A, and develop biomarkers to identify patients likely to benefit.